Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;80(8):1062-1069.
doi: 10.1136/annrheumdis-2020-219181. Epub 2021 May 7.

Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study

Felix Eckstein  1   2   3 , Marc C Hochberg  4 , Hans Guehring  5 , Flavie Moreau  6 , Victor Ona  6 , Asger Reinstrup Bihlet  7 , Inger Byrjalsen  7 , Jeppe Ragnar Andersen  7 , Benjamin Daelken  5 , Oliver Guenther  5 , Christoph Ladel  5 , Martin Michaelis  5 , Philip G Conaghan  8
Affiliations
Randomized Controlled Trial

Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study

Felix Eckstein et al. Ann Rheum Dis. 2021 Aug.

Abstract

Objective: The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results.

Methods: Patients were randomised to intra-articular sprifermin 100 µg or 30 µg every 6 months (q6mo) or 12 months, or placebo, for 18 months. The primary analysis was at year 2, with follow-up at years 3, 4 and 5. Additional post hoc exploratory analyses were conducted in patients with baseline minimum radiographic joint space width 1.5-3.5 mm and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain 40-90, a subgroup at risk (SAR) of progression.

Results: 378 (69%) patients completed the 5-year follow-up. A significant dose-response in total femorotibial joint cartilage thickness with sprifermin (trend test, p<0.001) and a 0.05 mm mean difference with sprifermin 100 µg q6mo versus placebo (95% CI 0.00 to 0.10; p=0.015) were sustained to year 5. WOMAC pain scores improved ~50% from baseline in all groups. No patient in the 100 µg q6mo group had replacement of the treated knee. 96%-98% of patients receiving sprifermin and 98% placebo reported adverse events, most were mild or moderate and deemed unrelated to treatment. Adverse event-related study withdrawals were <10%. Differentiation in WOMAC pain between sprifermin 100 µg q6mo and placebo in the SAR (n=161) at year 3 was maintained to year 5 (-10.08; 95% CI -25.68 to 5.53).

Conclusion: In the longest DMOAD trial reported to date, sprifermin maintained long-term structural modification of articular cartilage over 3.5 years post-treatment. Potential translation to clinical benefit was observed in the SAR.

Trial registration number: NCT01919164.

Keywords: biological therapy; knee; magnetic resonance imaging; osteoarthritis; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: FE is an employee and co-owner of Chondrometrics GmbH and reported receiving grants and consulting fees from Merck KGaA, Darmstadt, Germany, Samumed LLC, AbbVie, Bioclinica, Orthotrophix, Kolon TissueGene, Servier, Roche, Galapagos, Novartis, ICM and Healthlink. MH reports being the president of Rheumcon and receiving consulting fees from Bone Therapeutics, Bristol-Myers Squibb, Eli Lilly, Galapagos, IBSA Insititut Biotechniq SA, Novartis Pharma AG, Pfizer, Samumed LLC, Theralogix LLC and Kolon TissueGene. HG, BD, OG, CL and MM are employees of Merck KGaA, Darmstadt, Germany. FM and VO are employees of EMD Serono (a business of Merck KGaA, Darmstadt, Germany). ARB, IB and JRA are employees and shareholders in Nordic Bioscience. PGC has received consultancy or speaker’s bureau fees from AbbVie, AstraZeneca, BMS, EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Flexion Therapeutics, Galapagos, Kolon Tissue-Gene, Novartis, Pfizer, Samumed and Stryker.

Figures

Figure 1
Figure 1
Patient disposition. One patient was randomised to placebo but received sprifermin 30 µg at visit 7 and one patient was randomised to sprifermin 30 µg q12mo but received 100 µg at visit 3; these patients were included in the 30 µg q12mo and 100 µg q12mo groups, respectively, for the SAF analysis set. ITT, intention to treat; mITT, modified intention to treat; N, total number; n, subgroup sample size; q6mo, every 6 months; q12mo, every 12 months; SAF, safety; SAR, subgroup at risk.
Figure 2
Figure 2
Change in TFTJ cartilage thickness up to year 5. (A) Absolute change from baseline in TFTJ cartilage thickness (mm) and (B) difference from placebo in TFTJ cartilage thickness (mm) for the mITT population (n=494). (C) Absolute change from baseline in TFTJ cartilage thickness (mm) and (D) difference from placebo in TFTJ cartilage thickness (mm) for the SAR (n=161). Means and 95% CIs shown. *p<0.05, **p<0.005, ***p<0.001. BL, baseline; mITT, modified intention to treat; q6mo, every 6 months; q12mo, every 12 months; SAR, subgroup at risk; TFTJ, total femorotibial joint.
Figure 3
Figure 3
Change in MFTC and LFTC cartilage thickness up to year 5. Difference from placebo in cartilage thickness (mm) in the (A) MFTC and (B) LFTC for the mITT population (n=494). Absolute change from baseline in (C) MFTC and (D) LFTC cartilage thickness (mm) for the SAR (n=161). Means and 95% CIs shown. *p<0.05, **p<0.005, ***p<0.001. BL, baseline; LFTC, lateral femorotibial compartment; MFTC, medial femorotibial compartment; mITT, modified intention to treat; q6mo, every 6 months; q12mo, every 12 months; SAR, subgroup at risk; TFTJ, total femorotibial joint.
Figure 4
Figure 4
Change from baseline in WOMAC pain scores up to year 5 in the (A) ITT population (n=549) and (B) SAR (n=161). Means and 95% CIs shown. Δajd., adjusted mean difference (95% CI) to placebo at year 5; BL, baseline; ITT, intention to treat; q6mo, every 6 months; q12mo, every 12 months; SAR, subgroup at risk; WOMAC, Western Ontaria and McMaster Universities Osetoarthritis Index.
See this image and copyright information in PMC

Comment in

References

    1. Bannuru RR, Osani MC, Vaysbrot EE, et al. . OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:1578–89. 10.1016/j.joca.2019.06.011 - DOI - PubMed
    1. Kolasinski SL, Neogi T, Hochberg MC, et al. . 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020;72:220–33. 10.1002/art.41142 - DOI - PMC - PubMed
    1. Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. . Osteoarthritis. Nat Rev Dis Primers 2016;2:16072. 10.1038/nrdp.2016.72 - DOI - PubMed
    1. Hermann W, Lambova S, Muller-Ladner U. Current treatment options for osteoarthritis. Curr Rheumatol Rev 2018;14:108–16. 10.2174/1573397113666170829155149 - DOI - PubMed
    1. Karsdal MA, Michaelis M, Ladel C, et al. . Disease-Modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthritis Cartilage 2016;24:2013–21. 10.1016/j.joca.2016.07.017 - DOI - PubMed

Publication types

Substances

Associated data